{"disease":{"id":"corneal-neovascularization","name":"corneal neovascularization"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05659940","title":"Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.","phase":"","overall_status":"UNKNOWN","enrollment_count":66,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT04787471","title":"Corneal Crosslinking for Treatment of Corneal Neovascularization","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"Price Vision Group","has_results":false},{"nct_id":"NCT04620109","title":"Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":62,"lead_sponsor_name":"Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd","has_results":false},{"nct_id":"NCT05011916","title":"The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT02797704","title":"Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Rabin Medical Center","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}